Eltrombopag for Chemotherapy-induced Thrombocytopenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2020

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2025

Conditions
Chemotherapy-induced ThrombocytopeniaEltrombopag
Interventions
DRUG

Eltrombopag

The subjects will initiate treatment with 75 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 75 mg daily. Subjects whose platelet count ≤100×109/L,the eltrombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of eltrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks,already have reduced the dose of eltrombopag to 25mg once every other day during the treatment period, eltrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off eltrombopag if the platelet is greater than 50×109/L.

Trial Locations (1)

300020

RECRUITING

Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin

All Listed Sponsors
collaborator

Tianjin Medical University Cancer Institute and Hospital

OTHER

collaborator

Tianjin Medical University Second Hospital

OTHER

collaborator

Tianjin Third Central Hospital

OTHER

collaborator

Tianjin People's Hospital

OTHER

collaborator

Henan Cancer Hospital

OTHER_GOV

collaborator

The Second Affiliated Hospital of Kunming Medical University

OTHER

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER